嗜酸性粒细胞与中性粒细胞对COPD中ICS临床效应的预测价值
该研究纳入114例未使用过吸入性糖皮质激素(ICS)的COPD患者,来自GLUCOLD研究,随机接受ICS或安慰剂治疗并随访30个月。基线血嗜酸性粒细胞与其他 compartment 的嗜酸性粒细胞计数相关,但中性粒细胞无此相关性。基线嗜酸性粒细胞和中性粒细胞均不能预测ICS治疗6-30个月内的FEV1变化;活检嗜酸性粒细胞与ICS治疗期间症状加重相关,活检中性粒细胞与6个月ICS治疗时肺过度充气改善相关。
要点
- 血嗜酸性粒细胞可反映COPD患者肺内嗜酸性粒细胞水平,而血中性粒细胞不能反映肺内中性粒细胞。
- 基线嗜酸性粒细胞和中性粒细胞均不能预测ICS治疗6-30个月的FEV1变化。
- 活检嗜酸性粒细胞与ICS治疗期间症状加重相关,活检中性粒细胞与6个月ICS治疗时肺过度充气改善相关。
核心结论
- 在未使用ICS的COPD患者中,血嗜酸性粒细胞反映其他 compartment 的嗜酸性粒细胞,而中性粒细胞无此反映。
- 基线嗜酸性粒细胞和中性粒细胞均不能预测ICS治疗6-30个月内的肺功能变化。
- 活检嗜酸性粒细胞与ICS治疗期间呼吸症状加重相关,活检中性粒细胞与6个月ICS治疗时肺过度充气改善相关,值得进一步研究。
研究设计与样本
- 研究纳入114例未使用过ICS的COPD患者,来自GLUCOLD研究,接受ICS或安慰剂治疗并随访30个月。
- 基线时评估血、痰、气道壁活检和支气管肺泡灌洗液(BAL)中的细胞计数。
- 基线、6个月和30个月时评估FEV1、残气量/肺总量(过度充气)和临床COPD问卷。
主要发现
- 基线横断面分析显示,较高的血嗜酸性粒细胞与痰、活检和BAL中较高的嗜酸性粒细胞计数显著相关。
- 血中性粒细胞与其他 compartment 的中性粒细胞计数无显著相关性。
- 基线时任何 compartment 测量的嗜酸性粒细胞和中性粒细胞均不能预测纵向FEV1变化。
- 较高的基线活检嗜酸性粒细胞与6个月和30个月ICS治疗期间症状增加相关。
- 较高的活检中性粒细胞与6个月ICS治疗相比安慰剂时更明显的过度充气改善相关。
临床怎么用
- 血嗜酸性粒细胞可作为COPD患者肺内嗜酸性粒细胞炎症的替代标志物,但血中性粒细胞不能反映肺内中性粒细胞。
- 不应仅依据基线血嗜酸性粒细胞或中性粒细胞预测ICS对肺功能(FEV1)的长期疗效。
- 活检嗜酸性粒细胞和中性粒细胞与ICS治疗期间症状及过度充气变化的关联需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Inflammation is present to a variable degree and composition in patients with COPD. This study investigates associations between both eosinophils and neutrophils in blood, sputum, airway wall biopsies and bronchoalveolar lavage (BAL) and their potential use as biomarkers for clinical response to inhaled corticosteroids (ICS). METHODS: In total, 114 steroid-naïve COPD patients of the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study using ICS or placebo during 30-month follow-up were included. Cell counts in blood, sputum, biopsies and BAL were evaluated at baseline. In addition, at baseline, 6 and 30 months, forced expiratory flow in 1 s (FEV1 ), residual volume/total lung capacity (hyperinflation) and Clinical COPD Questionnaire were evaluated. RESULTS: Cross-sectional analyses at baseline showed that higher blood eosinophils were significantly associated with higher eosinophil counts in sputum, biopsies and BAL. However, blood neutrophils did not significantly correlate with neutrophil counts in the other compartments. Baseline eosinophils and neutrophils, in whichever compartment measured, did not predict longitudinal FEV1 changes. Higher baseline biopsy eosinophils were associated with an increase in symptoms during 6- and 30-month ICS treatment. In addition, higher biopsy neutrophils were associated with a more marked reduction in hyperinflation during 6-month ICS treatment compared with placebo. CONCLUSION: Our findings indicate that blood eosinophils reflect eosinophils in other compartments, in contrast to neutrophils, in ICS-naïve COPD patients. Both baseline eosinophils and neutrophils do not predict ICS-induced lung function changes over a period of 6-30 months. The associations of biopsy eosinophils with worsening respiratory symptoms and biopsy neutrophils with improvement in hyperinflation during ICS treatment deserve further investigation.
引用
- Hartjes FJ, Vonk JM, Faiz A, et al. Predictive value of eosinophils and neutrophils on clinical effects of ICS in COPD. Respirology. 2018. PMID: 29696728. doi:10.1111/resp.13312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。